COMPANY
AirNexis Therapeutics
AirNexis is developing AN01, a first of its kind dry powder inhaler for chronic obstructive pulmonary disease (COPD). From company website Source · Oct 12, 2026
Funding and NIH signals
- SEC Form D raise Raised $62M (Form D filed Mar 9, 2026). SEC Form D 0002116194-26-000001 (Mar 9, 2026)
Evidence (1 event)
- Mar 9, 2026 · SEC Form D 0002116194-26-000001
Name of Issuer: AirNexis Therapeutics, Inc.; CIK: 2116194; Address: Palo Alto, CA; Submission type: D; Filing date: 2026-03-09; Industry Group: Biotechnology; Date of First Sale: 2026-01-09; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 200000000; Total Amount Sold: 62000000; Federal exemptions: 06b
- Mar 9, 2026 · SEC Form D 0002116194-26-000001
Timeline
- Trial start Phase 1: A Trial to Assess Safety, Tolerability, and Pharmacokinetics of AN01 Inhalation Powder in Healthy Participants source ↗
Clinical trials (lead sponsor) 1
| Record | Title | Phase | Status | Start | Primary completion |
|---|---|---|---|---|---|
| NCT07554365 | A Trial to Assess Safety, Tolerability, and Pharmacokinetics of AN01 Inhalation Powder in Healthy Participants | Phase 1 | Completed | May 13, 2026 | Jun 29, 2026 (actual) |
Raises and investors new
- InvestorListed in the portfolio of OrbiMed (captured Oct 12, 2026). portfolio page ↗